Table 2. Cancer-specific mortality, overall mortality, BCR, metastatic disease, and hospital readmissions by stage and treatment group.

Variable		Locally advanced disease			Clinically localized disease
		Surgery (n=54)	Radiotherapy (n=35)	p-value	Surgery (n=66)	Radiotherapy (n=142)	p-value
Cancer-specific mortality				0.082			0.597
	Total person-years in follow-up	254	168		344	768
	Number of deaths due to prostate cancer	0	2		1	4
	Prostate cancer deaths per 1,000 person-years	0.0 (0.0–14.4)	11.9 (1.3–43.0)		2.9 (0.0–16.2)	5.2 (1.4–13.3)
Overall mortality				0.003			0.019
	Total person-years in follow-up	254	168		344	768
	Number of deaths due to any cause	1	8		4	29
	All-cause deaths per 1,000 person-years	3.9 (0.1–21.9)	47.6 (20.5–93.8)		11.6 (3.1–29.8)	37.8 (25.3–54.2)
Incidence of BCR				<0.001			0.897
	Person-years in follow-up free of BCR	155	150		297	699
	Number of men with BCR	32	7		12	27
	BCR per 1,000 person-years	207.0 (141.0–292.0)	46.7 (18.7–96.2)		40.4 (20.9–70.6)	38.6 (25.5–56.2)
Incidence of metastatic disease				0.275			0.409
	Person-years in follow-up free of metastatic disease	240	154		338	744
	Number of men with metastatic disease	6	7		4	14
	Metastatic disease per 1,000 person-years	25.0 (9.1–54.4)	45.5 (18.2–93.7)		11.8 (3.2–30.3)	18.8 (10.3–31.6)
Incidence of hospital readmissions				0.002			0.044
	Number of men with hospital readmissions	10	17		13	50
	Proportion of men with readmissions	18.5	48.6		19.7	35.2
	Hospital readmissions per 1,000 person-years	46.3 (22.2–85.1)	146.0 (85.3–235.0)	54.2	(30.3–89.3)	82.8 (61.8–109.0)

Values are presented as number only, hazard ratio (95% confidence interval), or percentage only.

BCR, biochemical recurrence.